Pathological complete response in breast cancer: Is it truly a surrogate for outcome?
Authors:
Open Access
- 1 April 2023
- journal article
- Published by Medknow in Cancer Research, Statistics, and Treatment
- Vol. 6 (2) , 232-234
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysisBMJ, 2021
- Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast CancerNew England Journal of Medicine, 2021
- Standardized Pathology Report for Breast CancerJournal of Breast Cancer, 2021
- Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-AnalysisCancer Research, 2020
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast CancerNew England Journal of Medicine, 2019
- Adjuvant Capecitabine for Breast Cancer after Preoperative ChemotherapyNew England Journal of Medicine, 2017
- Factors that predict recurrence later than 5 years after initial treatment in operable breast cancerWorld Journal of Surgical Oncology, 2016
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisThe Lancet, 2014
- Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer SubtypesJournal of Clinical Oncology, 2012
- Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohortThe Lancet, 2010